Data Shows Peregrine's VEA Compound Boosts Efficacy of Chemotherapeutic Agents

Peregrine Pharmaceuticals has announced that a paper published in the April 15 issue of Clinical Cancer Research shows the antibody-targeted VEA (vasopermeability enhancing agent) NHS76/PEP2 greatly enhanced the uptake and efficacy of a variety of chemotherapeutic agents in solid tumor models.

The publication contains data showing that NHS76/PEP2 pretreatment enhanced the efficacy of chemotherapy in tumors known to be sensitive to the specific drugs. In addition, the report shows that NHS76/PEP2 plus chemotherapy also generated responses in tumors normally resistant to specific therapies, such as MAD109 murine lung carcinoma treated with paclitaxel, vinblastine or 5-FU. Moreover, improvements in drug uptake were seen in as few as one to two hours following pretreatment with NHS76/PEP2.